概述

  • 产品名称Anti-LRP5抗体
    参阅全部 LRP5 一抗
  • 描述
    兔多克隆抗体to LRP5
  • 特异性This antibody is specific for LRP5 (C term). It has not yet been tested against endogenous LRP5, but on recombinant human LRP5 and mouse LRP5 proteins in transfected 293 cell lysates.
  • 经测试应用适用于: ICC/IF, IHC-P, WBmore details
  • 种属反应性
    与反应: Mouse, Human
  • 免疫原

    Synthetic peptide corresponding to Human LRP5 aa 1538-1567 (C terminal) conjugated to Keyhole Limpet Haemocyanin (KLH).
    Database link: O75197

  • 阳性对照
    • IHC-P: Human hepatocarcinoma tissue. ICC/IF: HepG2 cells.

性能

应用

Our Abpromise guarantee covers the use of ab38311 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ICC/IF Use a concentration of 1 - 5 µg/ml.
IHC-P 1/50 - 1/100.
WB 1/1000. Detects a band of approximately 179 kDa (predicted molecular weight: 179 kDa).

靶标

  • 功能Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Appears be required for postnatal control of vascular regression in the eye. Required for posterior patterning of the epiblast during gastrulation.
  • 组织特异性Widely expressed, with the highest level of expression in the liver.
  • 疾病相关Defects in LRP5 are the cause of vitreoretinopathy exudative type 4 (EVR4) [MIM:601813]. EVR4 is a disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. EVR4 inheritance can be autosomal dominant or recessive.
    Genetic variations in LRP5 are a cause of susceptibility to osteoporosis (OSTEOP) [MIM:166710]; also known as senile osteoporosis or postmenopausal osteoporosis. Osteoporosis is characterized by reduced bone mass, disruption of bone microarchitecture without alteration in the composition of bone. Osteoporotic bones are more at risk of fracture.
    Defects in LRP5 are the cause of osteoporosis-pseudoglioma syndrome (OPPG) [MIM:259770]; also known as osteogenesis imperfecta ocular form. OPPG is a recessive disorder characterized by very low bone mass and blindness. Individualy with OPPG are prone to develop bone fractures and deformations and have various eye abnormalities, including phthisis bulbi, retinal detachments, falciform folds or persistent vitreal vasculature.
    Defects in LRP5 are a cause of high bone mass trait (HBM) [MIM:601884]. HBM is a rare phenotype characterized by exceptionally dense bones. HBM individuals show otherwise a completely normal skeletal structure and no other unusual clinical findings.
    Defects in LRP5 are a cause of endosteal hyperostosis Worth type (WENHY) [MIM:144750]; also known as autosomal dominant osteosclerosis. WENHY is an autosomal dominant sclerosing bone dysplasia clinically characterized by elongation of the mandible, increased gonial angle, flattened forehead, and the presence of a slowly enlarging osseous prominence of the hard palate (torus palatinus). Serum calcium, phosphorus and alkaline phosphatase levels are normal. Radiologically, it is characterized by early thickening of the endosteum of long bones, the skull and of the mandible. With advancing age, the trabeculae of the metaphysis become thickened. WENHY becomes clinically and radiologically evident by adolescence, does not cause deformity except in the skull and mandible, and is not associated with bone pain or fracture. Affected patients have normal height, proportion, intelligence and longevity.
    Defects in LRP5 are the cause of osteopetrosis autosomal dominant type 1 (OPTA1) [MIM:607634]. Osteopetrosis is a rare genetic disease characterized by abnormally dense bone, due to defective resorption of immature bone. The disorder occurs in two forms: a severe autosomal recessive form occurring in utero, infancy, or childhood, and a benign autosomal dominant form occurring in adolescence or adulthood. OPTA1 is characterized by generalized osteosclerosis most pronounced in the cranial vault. Patients are often asymptomatic, but some suffer from pain and hearing loss. It appears to be the only type of osteopetrosis not associated with an increased fracture rate.
    Defects in LRP5 are the cause of van Buchem disease type 2 (VBCH2)[MIM:607636]. VBCH2 is an autosomal dominant sclerosing bone dysplasia characterized by cranial osteosclerosis, thickened calvaria and cortices of long bones, enlarged mandible and normal serum alkaline phosphatase levels.
  • 序列相似性Belongs to the LDLR family.
    Contains 4 EGF-like domains.
    Contains 3 LDL-receptor class A domains.
    Contains 20 LDL-receptor class B repeats.
  • 翻译后修饰Phosphorylation of cytoplasmic PPPSP motifs regulates the signal transduction of the Wnt signaling pathway through acting as a docking site for AXIN1.
  • 细胞定位Membrane. Endoplasmic reticulum. Chaperoned to the plasma membrane by MESD.
  • Information by UniProt
  • 数据库链接
  • 别名
    • BMND1 antibody
    • EVR1 antibody
    • EVR4 antibody
    • HBM antibody
    • Low density lipoprotein receptor related protein 5 antibody
    • Low density lipoprotein receptor related protein 7 antibody
    • Low-density lipoprotein receptor-related protein 5 antibody
    • LR3 antibody
    • LRP-5 antibody
    • Lrp5 antibody
    • LRP5_HUMAN antibody
    • LRP7 antibody
    • OPPG antibody
    • OPS antibody
    • OPTA1 antibody
    • Osteoporosis pseudoglioma syndrome antibody
    • VBCH2 antibody
    see all

Anti-LRP5 antibody 图像

  • All lanes : Anti-LRP5 antibody (ab38311) at 1/1000 dilution

    Lane 1 : recombinant human LRP5 transfected 293 cell lysates
    Lane 2 : mouse LRP5 transfected 293 cell lysates

    Lysates/proteins at 35 µg per lane.

    Secondary
    Peroxidase-conjugated goat anti-rabbit IgG (H+L) at 1/5000 dilution

    Predicted band size : 179 kDa
    Observed band size : 179 kDa

    Incubation time was overnight at 4°C. Blocking/Dilution buffer: 5% NFDM/TBST.

  • Immunohistochemistry (Formalin/PFA-fixed paraffin-embedded sections) analysis of human hepatocarcinoma tissue labelling LRP5 with ab38311. Tissue was fixed with formaldehyde and blocked with 3% BSA for 0.5 hour at 38°C; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody (1/25) for 1 hour at 37°C. A peroxidase-conjugated goat anti-rabbit polyclonal (ready to use) was used as the secondary antibody.

  • ICC/IF image of ab38311 stained HepG2 cells. The cells were 100% methanol fixed (5 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab38311, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

Anti-LRP5 antibody (ab38311)参考文献

This product has been referenced in:
  • Scholtysek C  et al. PPARß/d governs Wnt signaling and bone turnover. Nat Med 19:608-13 (2013). Mouse . Read more (PubMed: 23542786) »
  • Almeida MQ  et al. Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum Mol Genet 19:1387-98 (2010). WB, IHC-P ; Mouse . Read more (PubMed: 20080939) »

See all 2 Publications for this product

Product Wall

Thank you very much for your call today and for letting us know about the trouble with ab38311.

I apologize that this antibody did not work as expected. As discussed, I'm sending a free of charge vial of ab36121 on the order ***. This should ...

Read More

Thank you very much again for your patience while I have been working with the lab regarding your enquiry.

The antibody ab38311 has now been tested in IHC-P on human breast carcinoma tissue, and the image is attached. A 1:10 dilution was used...

Read More

Thank you for calling Abcam.

Please find attached the IHC-P protocol that was used to test ab38311.

If there is anything else I can help you with, please let me know.

Thank you very much for your previous call and for your patience while I have been intouch with the lab regarding ab38311.

The antibody has only been tested against the recombinant protein and transfected lysates in Western blot at this time....

Read More

Thank you for your enquiry. I am sorry to hear that you are experiencing difficulties with this product ab38311 in western blot. Often it is possible to make suggestions that help resolve problems. We will happily offer technical support and in the ...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"